NCT05716295View on ClinicalTrials.gov

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

MDK-703

MDK-703 will be administered as specified under Arm description.

DRUG

Checkpoint Inhibitor, Immune

Checkpoint inhibitor will be administered as specified under Arm description.

Trial Locations (6)

22031

NEXT Oncology Virginia, Fairfax

28078

Carolina BioOncology Institute, Huntersville

34232

Sarah Cannon Research Institute (Florida Cancer Specialists), Sarasota

75251

Mary Crowley Cancer Research, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

78758

NEXT Oncology Austin, Austin

Sponsors

Lead Sponsor

Medikine, Inc.
All Listed Sponsors
lead

Medikine, Inc.

INDUSTRY

NCT05716295 - A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter